vs
德康医疗（DXCM）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
德康医疗的季度营收约是Rollins, Inc.的1.4倍（$1.3B vs $906.4M），德康医疗净利率更高（21.2% vs 11.9%，领先9.3%），德康医疗同比增速更快（21.6% vs 10.2%），过去两年德康医疗的营收复合增速更高（12.0% vs 0.8%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
DXCM vs ROL — 直观对比
营收规模更大
DXCM
是对方的1.4倍
$906.4M
营收增速更快
DXCM
高出11.4%
10.2%
净利率更高
DXCM
高出9.3%
11.9%
两年增速更快
DXCM
近两年复合增速
0.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $906.4M |
| 净利润 | $267.3M | $107.8M |
| 毛利率 | 62.9% | — |
| 营业利润率 | 25.6% | 16.1% |
| 净利率 | 21.2% | 11.9% |
| 营收同比 | 21.6% | 10.2% |
| 净利润同比 | 153.6% | 2.5% |
| 每股收益（稀释后） | $0.67 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMROL
| Q1 26 | $1.3B | $906.4M | ||
| Q4 25 | $1.3B | $912.9M | ||
| Q3 25 | $1.2B | $1.0B | ||
| Q2 25 | $1.2B | $999.5M | ||
| Q1 25 | $1.0B | $822.5M | ||
| Q4 24 | $1.1B | $832.2M | ||
| Q3 24 | $994.2M | $916.3M | ||
| Q2 24 | $1.0B | $891.9M |
净利润DXCMROL
| Q1 26 | $267.3M | $107.8M | ||
| Q4 25 | $267.3M | $116.4M | ||
| Q3 25 | $283.8M | $163.5M | ||
| Q2 25 | $179.8M | $141.5M | ||
| Q1 25 | $105.4M | $105.2M | ||
| Q4 24 | $151.7M | $105.7M | ||
| Q3 24 | $134.6M | $136.9M | ||
| Q2 24 | $143.5M | $129.4M |
毛利率DXCMROL
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
营业利润率DXCMROL
| Q1 26 | 25.6% | 16.1% | ||
| Q4 25 | 25.6% | 17.5% | ||
| Q3 25 | 20.1% | 21.9% | ||
| Q2 25 | 18.4% | 19.8% | ||
| Q1 25 | 12.9% | 17.3% | ||
| Q4 24 | 17.0% | 18.1% | ||
| Q3 24 | 15.3% | 20.9% | ||
| Q2 24 | 15.7% | 20.4% |
净利率DXCMROL
| Q1 26 | 21.2% | 11.9% | ||
| Q4 25 | 21.2% | 12.8% | ||
| Q3 25 | 23.5% | 15.9% | ||
| Q2 25 | 15.5% | 14.2% | ||
| Q1 25 | 10.2% | 12.8% | ||
| Q4 24 | 13.6% | 12.7% | ||
| Q3 24 | 13.5% | 14.9% | ||
| Q2 24 | 14.3% | 14.5% |
每股收益（稀释后）DXCMROL
| Q1 26 | $0.67 | $0.22 | ||
| Q4 25 | $0.67 | $0.24 | ||
| Q3 25 | $0.70 | $0.34 | ||
| Q2 25 | $0.45 | $0.29 | ||
| Q1 25 | $0.27 | $0.22 | ||
| Q4 24 | $0.37 | $0.22 | ||
| Q3 24 | $0.34 | $0.28 | ||
| Q2 24 | $0.35 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $2.7B | $1.4B |
| 总资产 | $6.3B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资DXCMROL
| Q1 26 | $917.7M | $116.5M | ||
| Q4 25 | $917.7M | $100.0M | ||
| Q3 25 | $1.8B | $127.4M | ||
| Q2 25 | $1.2B | $123.0M | ||
| Q1 25 | $904.9M | $201.2M | ||
| Q4 24 | $606.1M | $89.6M | ||
| Q3 24 | $621.2M | $95.3M | ||
| Q2 24 | $939.2M | $106.7M |
总债务DXCMROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益DXCMROL
| Q1 26 | $2.7B | $1.4B | ||
| Q4 25 | $2.7B | $1.4B | ||
| Q3 25 | $2.7B | $1.5B | ||
| Q2 25 | $2.6B | $1.4B | ||
| Q1 25 | $2.3B | $1.4B | ||
| Q4 24 | $2.1B | $1.3B | ||
| Q3 24 | $2.0B | $1.3B | ||
| Q2 24 | $2.4B | $1.2B |
总资产DXCMROL
| Q1 26 | $6.3B | $3.2B | ||
| Q4 25 | $6.3B | $3.1B | ||
| Q3 25 | $7.5B | $3.2B | ||
| Q2 25 | $7.3B | $3.2B | ||
| Q1 25 | $6.8B | $2.9B | ||
| Q4 24 | $6.5B | $2.8B | ||
| Q3 24 | $6.4B | $2.8B | ||
| Q2 24 | $6.8B | $2.8B |
负债/权益比DXCMROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $118.4M |
| 自由现金流经营现金流 - 资本支出 | — | $111.2M |
| 自由现金流率自由现金流/营收 | — | 12.3% |
| 资本支出强度资本支出/营收 | — | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | — | $621.1M |
8季度趋势，按日历期对齐
经营现金流DXCMROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $294.0M | $164.7M | ||
| Q3 25 | $659.9M | $191.3M | ||
| Q2 25 | $303.0M | $175.1M | ||
| Q1 25 | $183.8M | $146.9M | ||
| Q4 24 | $301.4M | $188.2M | ||
| Q3 24 | $199.5M | $146.9M | ||
| Q2 24 | $279.4M | $145.1M |
自由现金流DXCMROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $192.1M | $159.0M | ||
| Q3 25 | $579.4M | $182.8M | ||
| Q2 25 | $208.9M | $168.0M | ||
| Q1 25 | $96.8M | $140.1M | ||
| Q4 24 | $176.8M | $184.0M | ||
| Q3 24 | $88.3M | $139.4M | ||
| Q2 24 | $213.3M | $136.4M |
自由现金流率DXCMROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 15.3% | 17.4% | ||
| Q3 25 | 47.9% | 17.8% | ||
| Q2 25 | 18.1% | 16.8% | ||
| Q1 25 | 9.3% | 17.0% | ||
| Q4 24 | 15.9% | 22.1% | ||
| Q3 24 | 8.9% | 15.2% | ||
| Q2 24 | 21.2% | 15.3% |
资本支出强度DXCMROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 8.1% | 0.6% | ||
| Q3 25 | 6.7% | 0.8% | ||
| Q2 25 | 8.1% | 0.7% | ||
| Q1 25 | 8.4% | 0.8% | ||
| Q4 24 | 11.2% | 0.5% | ||
| Q3 24 | 11.2% | 0.8% | ||
| Q2 24 | 6.6% | 1.0% |
现金转化率DXCMROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | 1.10× | 1.41× | ||
| Q3 25 | 2.33× | 1.17× | ||
| Q2 25 | 1.69× | 1.24× | ||
| Q1 25 | 1.74× | 1.40× | ||
| Q4 24 | 1.99× | 1.78× | ||
| Q3 24 | 1.48× | 1.07× | ||
| Q2 24 | 1.95× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
